Abate As Industries Ltd

AGM Details

• Date and time: 16 September 2026 at 3:00 PM IST
• Mode: VC/OAVM
• Cut-off date for e-voting: 9 September 2026
• Book closure: 10 September 2026 to 16 September 2026
• Remote e-voting window: 13 September 2026 09:00 IST to 15 September 2026 17:00 IST

ordinary business

• Adopt standalone financial statements for FY 2025-26
• Adopt consolidated financial statements for FY 2025-26
• Appoint Rajesh Puthussery as Director (retiring by rotation)
• Appoint Abdul Nazar Jamal Kizhisseri Muhammed as Director (retiring by rotation)

Special business

• Re-appoint Dr Muhemmed Swadique as Executive Director for five years
• Re-appoint Ms Julie G Varghese as Independent Director for second term (Aug 2026–Aug 2031)
• Re-appoint Ms Indu Kamala Ravindran as Independent Director for second term (Dec 2026–Dec 2031)
• Regularize appointment of Aboobaker Vattamkandathil as Non-Executive Independent Director
• Alter MOA: expand main object to healthcare services

AGM & annual report access

• AGM scheduled for 16 September 2026 at 03:00 PM IST via VC/OAVM
• Annual Report for FY2025-26 and AGM Notice available on abateas.com; exact path /annual-report/
• Web-link provided for non-registered email holders per Benpos 14 August 2026

KYC & dematerialisation reminders

• Reminder to update KYC details and dematerialize physical securities per SEBI circular
• Forms ISR1-ISR3 and SH-13/SH-14 prescribed for updating nominations and KYC details

Governance note

• Company name: Abate AS Industries Limited (formerly Trijal Industries Limited)

AGM and book closure details

• AGM scheduled for 16 September 2026 at 03:00 PM IST via VC/OAVM.
• Book closure from 10 September 2026 to 16 September 2026 (inclusive) for AGM.
• Cut-off date for eligibility for remote e-voting and AGM voting: 9 September 2026.
• Remote e-voting opens 13 September 2026 at 09:00 IST and closes 15 September 2026 at 17:00 IST.

Financial performance

• Consolidated total income: ₹1,617.37 million; revenue from operations: ₹1,594.09 million.
• Standalone PAT: ₹1.54 crore; Consolidated PAT: ₹12.30 crore.
• Consolidated revenue growth vs 2024-25: substantial increase with international contribution.
• Earnings per share: ₹0.54 consolidated; ₹0.59 prior year.
• Intercompany eliminations: ₹10.30 million in consolidation.
• Dividend: not recommended for FY2025-26.

Capital structure & capital actions

• Bonus issue: 7,88,03,228 new shares; post-bonus paid-up capital ₹157.60 crore.
• Authorized capital increased to ₹158 crore (Phase I) and ₹200 crore (Phase II).
• Share swap via preferential allotment: 7,37,87,128 shares issued on Feb 25, 2025.
• Shareholding after swap: Promoter group 27.56%; Public 72.44%.

Business development & strategy

• Plan to build a global network of 44 eye hospitals.
• New Manjeri superspecialty eye hospital planned; Bahrain expansion underway.
• MOA object clause expanded to healthcare infra and digital health.
• Education plans include a private healthcare university; strategic partnerships contemplated.
• Expansion includes international patient services and medical tourism.

Operations & segment performance

• Sky International Trading WLL contributed ₹1,234.50 million revenue.
• Prudential Management Services: ₹309.50 million revenue.
• Salamath Import & Exports: ₹60.38 million revenue.
• Group procedures: 9,147; Perinthalmanna center ~73% of procedures.
• Cataract surgeries 55%; retina injections 32%; retina surgeries 8%.

Governance & controls

• Board comprises 16 directors; 8 Independent; women directors on board.
• Ambramoli Purushothaman resigned 27 Nov 2025; Harikumar added 12 Feb 2026.
• Independent Directors met 12 Feb 2026; disclosures and familiarisation documented.
• SOP fines paid to BSE for 2024-25; no material non-compliance reported.
• Secretarial audit: no qualifications; governance policies published on website.

Subsidiaries & associate

• Subsidiaries: Salamath Import & Exports Private Limited, Prudential Management Services Private Limited, Sky International Trading WLL.
• Associate: SAIA Educational Support Services WLL.
• Consolidation includes 3 subsidiaries and 1 associate; intercompany eliminations ₹10.30 million.
• Cross-border Bahrain operations with international strategic significance.

Audit & disclosures

• Statutory Auditor: Mahesh C Solanki & Co; Secretarial Auditor: Lakshmmi Subramanian & Associates.
• Secretarial audits for Salamath and Prudential: unqualified.
• Form MGT-9 not filed; annual return hosted on company website.
• Related party transactions are at arm's length; detailed in AOC-2.

Outlook & risks

• Opportunities: telemedicine, digital health, acquisitions, and medical tourism.
• Risks: regulatory changes, talent retention, cybersecurity, inflation, competition.
• Management focus on governance, capital discipline, and stakeholder value.

Abate As Industries – Q1 2026 results ads

• Publishes unaudited standalone and consolidated Q1 2026 results; newspaper ads on 15 August 2026.
• Ads published in Trinity Mirror (English) and Makkal Kural (Tamil).
• Complies with Regulations 30, 33, 47 of Listing Regulations.

Salonacotspin Limited – Q1 2026 results approval

• Board approved the quarter ended 30 June 2026 financial results.
• Results to be hosted on NSE site and the company's investor website.
• Board approval on 13 August 2026; filing date 14 August 2026.

Financial results and AGM logistics

• Standalone and Consolidated unaudited quarterly results for quarter ended June 30, 2026 approved.
• Audit Committee approved; results under Ind AS 34 with limited review by Mahesh C. Solanki & Co.
• AGM notice issued with 35% Annual Report for FY2025-26.
• AGM fixed for 16 September 2026 at 03:00 PM via video conferencing.
• Book closure, cut-off date, and remote e-voting period fixed.
• CDSL appointed as e-voting facilitator; Lakshmmi Subramanian & Associates as Scrutinizer.

Board appointments and governance

• Appointed Mr. Aboobaker Vattamkandathil as Additional Non-Executive Independent Director effective 13 August 2026.
• Re-appointment of Dr. Muhammed Swadique as Executive Director commencing 14 Aug 2026, subject to member approval.
• Re-appointment of Ms. Julie G Varghese as Independent Director from 14 Aug 2026 to 13 Aug 2031.
• Re-appointment of Ms. Indu Kamala Ravindran as Independent Director from 28 Dec 2026 to 27 Dec 2031.
• Alteration of MOA main object to broaden healthcare scope.

Regulatory and accounting notes

• Deferred Tax Asset: standalone ₹9.53 lakh; consolidated ₹320.76 lakh; no material impact expected.
• New Labour Codes assessment: current wage structure compliant; no material impact in Q1 2026.
• Independent Auditor's Review: some subsidiaries not reviewed; conclusion not modified.

Key Agenda Items

• Consider and approve standalone and consolidated unaudited financial results for quarter ended 30 June 2026.
• Fix day, date, and time for the ensuing Annual General Meeting for 2025-26.
• Consider and approve AGM Notice, Board’s Report, and Secretarial Audit Report.
• Set date for book closure.
• Set e-voting entitlement cut-off date and e-voting window.
• Appoint M/s Lakshmmi Subramanian & Associates as E-voting Scrutinizer.
• Appoint intermediaries like CDSL/NSDL for E-Voting.
• Appoint Mr. Aboobaker Vattamkandathil as Additional Independent Director.

Dematerialisation status

• Security received for dematerialisation in the quarter confirmed to depositories.
• Securities dematerialised were listed on exchanges where existing securities are listed.
• Physical certificates for dematerialisation were mutilated and cancelled; depository's name substituted as registered owner.